title: Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma.
abstract: A 14-year-old girl with metastatic renal cell carcinoma was treated with nephrectomy, interferon, and several lines of the targeted agents sorafenib, bevacizumab, sunitinib, and everolimus, either alone or in combination. Treatment was well tolerated, but the patient developed hypothyroidism and significant hypertension with bevacizumab and sunitinib. She responded to all agents and was given radiation treatment twice at the time of symptomatic disease progression; she died 33 months from diagnosis.
authors.affiliation: Onco-ematologia Pediatrica, Ospedale Pediatrico Bambino Gesù- IRCCS, Roma, Italy. mdebora.depasquale@opbg.net
authors.forename: Maria Debora
authors.initials: MD
authors.lastname: De Pasquale
authors.forename: Rosanna
authors.initials: R
authors.lastname: Pessolano
authors.forename: Renata
authors.initials: R
authors.lastname: Boldrini
authors.forename: Ilaria
authors.initials: I
authors.lastname: Ilari
authors.forename: Alberto
authors.initials: A
authors.lastname: Donfrancesco
authors.forename: Enrico
authors.initials: E
authors.lastname: Cortesi
authors.forename: Alessandro
authors.initials: A
authors.lastname: Jenkner
mesh_terms: D000293:Adolescent; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates / Q000627:therapeutic use*; D000068258:Bevacizumab; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D003131:Combined Modality Therapy; D000068338:Everolimus; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D009392:Nephrectomy; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011725:Pyridines / Q000627:therapeutic use*; D020123:Sirolimus / Q000031:analogs & derivatives / Q000627:therapeutic use; D000077157:Sorafenib
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011725:Pyridines; D009536:Niacinamide; D000068258:Bevacizumab; D000068338:Everolimus; D000077157:Sorafenib; D020123:Sirolimus